GSK And Oxford To Collaborate On Neoantigen Vaccines To Prevent Cancer

The potentially groundbreaking approach would use immunotherapy or targeted therapies against pre-cancerous cells to prevent cancer from developing at all.

Oxford, UK — GSK is extending its existing relationship with the University of Oxford, home to world-class academic biomedical research. • Source: Shutterstock

GSK is extending its relationship with the University of Oxford to research the potential of cancer prevention through vaccine-like immunotherapies.

The GSK-Oxford Cancer Immuno-Prevention Programme will conduct translational research, exploring pre-cancer biology to generate insights on how cancer develops in humans, with

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

GSK And Oxford To Collaborate On Neoantigen Vaccines To Prevent Cancer

Read the full article – start your free trial today!

More from R&D

More from Business